Loehrer, Philipp Alexander http://orcid.org/0000-0002-5279-2156
Schumacher, Wibke
Jost, Stefanie T.
Silverdale, Monty
Petry-Schmelzer, Jan Niklas http://orcid.org/0000-0003-0749-3840
Sauerbier, Anna
Gronostay, Alexandra
Visser-Vandewalle, Veerle http://orcid.org/0000-0002-5274-7929
Fink, Gereon R. http://orcid.org/0000-0002-8230-1856
Evans, Julian
Krause, Max http://orcid.org/0000-0002-4355-165X
Rizos, Alexandra
Antonini, Angelo http://orcid.org/0000-0003-1040-2807
Ashkan, Keyoumars
Martinez-Martin, Pablo
Gaser, Christian http://orcid.org/0000-0002-9940-099X
Ray Chaudhuri, K. http://orcid.org/0000-0003-2815-0505
Timmermann, Lars
Baldermann, Juan Carlos http://orcid.org/0000-0001-5851-9268
Dafsari, Haidar S. http://orcid.org/0000-0001-8849-4233
,
Funding for this research was provided by:
Philipps-Universität Marburg
Stiftung zur Förderung junger Neurowissenschaftler Professor Klaus Thiemann Foundation
Universität zu Köln (Koeln Fortune Program, Cologne Clinician Scientist Program, KoelnFortune program)
Prof. Klaus Thiemann Foundation Brandau-Laibach-Foundation
Deutsche Forschungsgemeinschaft (FI 773/15-464 1, 431549029-C07)
DH | National Institute for Health Research
International Parkinson and Movement Disorder Society
Clinical Research Network (CRN) South London
EC | Horizon 2020 Framework Programme (825785, 101016902)
Ministero dell‘Istruzione, dell’Università e della Ricerca (ARS01_01081)
Fondazione Cassa di Risparmio di Padova e Rovigo
Parkinson’s UK
Parkinson’s Foundation
Wellcome Trust
Kirby Laing Foundation
EU Joint Programme – Neurodegenerative Disease Research
Prof. Klaus Thiemann Foundation Felgenhauer Foundation
Article History
Received: 15 June 2023
Accepted: 26 March 2024
First Online: 26 April 2024
Competing interests
: PAL was supported by the SUCCESS-Program of the Philipps-University of Marburg, the ‘Stiftung zur Förderung junger Neurowissenschaftler’, and the Prof. Klaus Thiemann Foundation in the German Society of Neurology. WS was supported by the Koeln Fortune Program/Faculty of Medicine, University of Cologne, and reports no financial relationships with commercial interests. STJ was funded by the Prof. Klaus Thiemann Foundation and the Brandau-Laibach-Foundation, outside of the submitted work. MS has received honoraria from Bial, Britannia, and Medtronic. JNPS is funded by the Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/ University of Cologne; and by the German Research Foundation (DFG, FI 773/15-464 1). AS reports no financial disclosures. AG reports no financial disclosures. VVV reports compensation for contributions to advisory boards and congresses for Medtronic, Boston Scientific, and Livanova. GRF serves as an editorial board member of Cortex, Neurological Research and Practice, NeuroImage: Clinical, Zeitschrift für Neuropsychologie, DGNeurologie, and Info Neurologie & Psychiatrie; receives royalties from the publication of the books Funktionelle MRT in Psychiatrie und Neurologie, Neurologische Differentialdiagnose, and SOP Neurologie; receives royalties from the publication of the neuropsychological tests KAS and Köpps; received honoraria for speaking engagements from Deutsche Gesellschaft für Neurologie (DGN) and Forum für medizinische Fortbildung FomF GmbH. JE reports no financial disclosures. MK was funded by the Koeln Fortune program of the Medical Faculty of the University of Cologne and reports no financial relationships with commercial interests. AR received funding from the National Institute for Health and Care Research (NIHR), the Clinical Research Network (CRN) in South London, and grant funding from the International Parkinson and Movement Disorders Society (MDS). AA received compensation for consultancy and speaker-related activities from UCB, Boehringer–Ingelheim, Ever Pharma, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Theravance Biopharma, Jazz Pharmaceuticals, Roche, and Medscape. He receives research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020 Grant 825785, Horizon 2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation, Movement Disorders Society for NMS Scale validation. He serves as a consultant for Boehringer–Ingelheim for legal cases on pathological gambling. KA has received honoraria for educational meetings, travel, and consultancy from Medtronic, St. Jude Medical and Boston Scientific. PMM received honoraria from the International Parkinson and Movement Disorder Society (IPMDS) for the management of the Clinical Outcome Assessment Program. CG reports no financial disclosures. KRC received grants (IIT) from Britannia Pharmaceuticals, AbbVie, UCB, GKC, EU Horizon 2020, Parkinson’s UK, NIHR, Parkinson’s Foundation, Wellcome Trust, Kirby Laing Foundation, MRC; royalties or licenses from Oxford (book), Cambridge publishers (book), MAPI institute (KPPS, PDSS 2); consulting fees, support for attending meetings or travel, and participated on data safety monitoring board or advisory board for AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, Therevance, Scion, Britannia, Acadia, 4D Pharma, and Medtronic; and served as a committee chair for MDS (unpaid) and EAN (unpaid). LT received payments as a consultant for Medtronic Inc. and Boston Scientific and received honoraria as a speaker on symposia sponsored by Bial, Zambon Pharma, UCB Schwarz Pharma, Desitin Pharma, Medtronic, Boston Scientific, and Abbott. The institution of LT, not LT personally, received funding from the German Research Foundation, the German Ministry of Education and Research, and Deutsche Parkinson Vereinigung. JCB is funded by Else Kroener-Fresenius-Stiftung (2022_EKES.23) and receives funding from the German Research Foundation (Project ID 431549029-C07). HSD was funded by the EU Joint Program – Neurodegenerative Disease Research (JPND), the Prof. Klaus Thiemann Foundation in the German Society of Neurology, the Felgenhauer Foundation, the Koeln Fortune program of the Medical Faculty of the University of Cologne and has received honoraria by Everpharma, Kyowa Kirin, Bial, Oruen, and Stadapharm.